This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:To assess benefits and harms of first-in-class angiotensin receptor-neprilysin inhibitor sacubitril/valsartan (LCZ696) as compared to angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) in chronic heart failure (HF) patients with either reduced, mid-range, or preserved ejection fraction.LCZ696 (sacubitril/valsartan) for patients with heart failure (Protocol)